ArtNr |
LEIN-LT7000-500ug |
Hersteller |
Leinco Technologies
|
Menge |
500 ug |
Quantity options |
100 ug
500 ug
|
Kategorie |
|
Typ |
Antibody Primary |
Applikationen |
WB, IHC, ELISA |
Clon |
1C7C7 |
Specific against |
Virus, SARS-CoV-2 |
Purity |
≥95% monomer by analytical SEC |
NCBI |
43740575 |
ECLASS 10.1 |
32160702 |
ECLASS 11.0 |
32160702 |
UNSPSC |
12352203 |
Versandbedingung |
Gekühlt |
Lieferbar |
|
Manufacturer - Applications |
Quality Tested by Leinco ELISA IHC WB |
Manufacturer - Category |
Primary Monoclonal Antibodies>Infectious Diseases|Monoclonal Antibodies|Recombinant Antibodies|SARS-CoV-2 |
Manufacturer - Targets |
SARS-CoV-2 Nucleocapsid (N) |
Country of Origin |
USA |
Shipping Temperature |
Ships Overnight on Blue Ice |
Storage Conditions |
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
Product Description |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively 3, 4. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex 5. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways 6, 7. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein 8. It is also immunogenic, and antibodies 8, 9 and memory T cells 10, 11 targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 12. The N protein also contributes to immune evasion by antagonizing antiviral RNAi 13, suggesting its potential value as a targeted therapeutic. |
Background |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively 3, 4. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex 5. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways 6, 7. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein 8. It is also immunogenic, and antibodies 8, 9 and memory T cells 10, 11 targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 12. The N protein also contributes to immune evasion by antagonizing antiviral RNAi 13, suggesting its potential value as a targeted therapeutic. |
Other Applications Reported In Literature |
FC |
PubMed |
SARS-CoV-2 Nucleocapsid (N) |
Manufacturer - Research Area |
COVID-19, Viral |
Manufacturer - Expression host |
HEK-293 |
Manufacturer - Specificity |
Anti-SARS-CoV-2 Nucleocapsid, clone 1C7C7, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. |
RRID |
AB_2893978 |
Concentration |
≥1.0 mg/ml |
Formulation |
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
Antigen Distribution |
The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2. |
Immunogen |
Recombinant nucleoprotein of SARS-CoV (severe acute respiratory syndrome) |
Additonal Information |
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.